Mytide Therapeutics, Inc

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

Emulate Inc, based in Boston, MA, offers a cutting-edge platform for modeling the holistic journey of solid tumor cell therapy through organ chips. Their innovative technology allows researchers to simulate key processes such as vascular administration, endothelial attachment, T cell migration, and antigen-specific killing in a vascularized cancer cell line model. With a focus on reducing translational failure and improving human disease research, Emulate's human emulation system provides unparalleled insights into the inner workings of human biology. Their platform, comprised of instruments, consumables, and software, is user-friendly and flexible, offering researchers a powerful tool for advancing research and drug development in various fields such as cancer gene therapy, immunology, infectious disease, and neuroscience. Generated from the website

ExQor Technologies Inc, based in Boston, MA, is pioneering a unique biologic aimed at restoring cognitive capabilities by regenerating damaged neurons and their connections, specifically targeting neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementia. Unlike conventional drugs that merely delay disease progression, ExQor's innovative approach holds promise for treating various central nervous system disorders, including depression. The company is actively preparing its first Investigational New Drug (IND) applications to the FDA for addressing cognitive impairments associated with dementia. Additionally, ExQor is advancing diagnostic programs utilizing MRI and EEG technologies to detect early-stage Alzheimer's and mild cognitive impairment, which could lead to personalized treatment solutions and significant advancements in global healthcare. Generated from the website